SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
Company: Sanofi (as reported in metadata)
Filing Type: Form 13F Information Table
Reporting Period: The filing text does not explicitly state the reporting period end date, though metadata indicates "2026 Mar 31". The document lists holdings as of the filing date.
Context: This filing discloses equity securities held by Sanofi with a market value exceeding $100 million, as required by the Securities Exchange Act of 1934.
Key Financial Metrics and Holdings
The filing details specific equity positions. Aggregate financial metrics such as total revenue, profit, cash flow, or debt are not provided in this specific document.
| Issuer Name | Title of Class | Shares/Amount | Value (USD) | Voting Authority |
|---|---|---|---|---|
| Inhibrx Biosciences, Inc. | COM | 1,157,926 | $77,847,365 | Sole |
| MeiraGTx Holdings plc | COM | 12,197,737 | $105,632,402 | Sole |
| Novavax | COM | 6,880,481 | $56,007,115 | Sole |
| AnaptysBio | COM | 821,917 | $30,384,545 | Sole |
| Immuneering Corp | CLASS A COM | 2,708,559 | $14,274,106 | Sole |
| Eledon | COM | 814,980 | $2,510,138 | Sole |
| Q32 Bio Inc. | COM | 244,083 | $1,567,013 | Sole |
| MapLight Therapeutics Inc. | COM | 912,041 | $18,541,794 | Sole |
| Agomab Therapeutics NV | SPONSORED ADS | 2,783,096 | $29,194,677 | Sole |
Material Changes
The filing text does not provide comparative data from the prior period; therefore, material changes in holdings cannot be determined from this document alone.
Guidance, Outlook, and Risks
Management Commentary: None provided in this filing.
Risks and Contingencies: The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness. No specific operational risks or contingencies are detailed in the text.
Key Facts for Investor Verification
- Portfolio Focus: Sanofi holds significant positions in biotechnology and vaccine companies, with MeiraGTx Holdings plc being the largest disclosed position by value ($105.6M).
- Voting Control: Sanofi exercises "Sole" voting authority for all listed securities, indicating direct control over voting decisions for these holdings.
- Data Limitations: This Form 13F only reports holdings above a specific threshold and does not reflect the company's overall financial health, revenue, or debt levels.
- Reporting Date: Verify the exact quarter end date against the official filing header, as the provided text contains metadata suggesting "2026 Mar 31" but lacks an explicit date in the body.